The effects of cholesterol on learning and memory

Neuroscience and Biobehavioral Reviews

Volumn 34, Issue 8, 2010, Pages 1366-1379

  Schreurs, Bernard G ^a  

^a WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

24S hydroxcholesterol; Alzheimer's disease; Apolipoprotein E; ATP binding cassette transporters; Cholesterol fed rabbit; Classical conditioning; Eyeblink conditioning; Fear conditioning; Low density lipoprotein receptors; Statins; Water maze

Indexed keywords

26 HYDROXYCHOLESTEROL; ABC TRANSPORTER; APOLIPOPROTEIN E; ATORVASTATIN; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIVER X RECEPTOR; LOW DENSITY LIPOPROTEIN RECEPTOR; PLACEBO; SIMVASTATIN;

ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; BRAIN FUNCTION; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM; CHOLESTEROL INTAKE; CHOLESTEROL METABOLISM; CHOLESTEROL SYNTHESIS; CHOLESTEROL TRANSPORT; CLINICAL TRIAL; COGNITION; COGNITIVE DEFECT; CONDITIONED REFLEX; DRUG MECHANISM; DRUG PENETRATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; HUMAN; HYPERCHOLESTEROLEMIA; INTELLIGENCE TEST; LEARNING; MAZE TEST; MEMORY; MEMORY DISORDER; METABOLIC REGULATION; MULTIINFARCT DEMENTIA; MUTATIONAL ANALYSIS; NEUROPATHOLOGY; NONHUMAN; PASSIVE AVOIDANCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; TASK PERFORMANCE;

ADENOSINE TRIPHOSPHATE; ANIMALS; APOLIPOPROTEINS E; CHOLESTEROL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LEARNING; MEMORY; ORPHAN NUCLEAR RECEPTORS; RECEPTORS, LDL;

EID: 77954175073     PISSN: 01497634     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neubiorev.2010.04.010     Document Type: Review

References (240)

1. Akram A., Schmeidler J., Kastel P., Hof P.R., Haroutunian V. Increased expression of cholesterol transporter ABCA1 is highly correlated with severity of dementia in AD hippocampus. Brain Res. 2010, 1318:167-177.
2. Arndt S.S., Surjo D. Methods for behavioural phenotyping of mouse mutants. How to keep the overview. Behav. Brain Res. 2001, 125:39-42.
3. Arvanitakis Z., Schneider J.A., Wilson R.S., Bienias J.L., Kelly J.F., Evans D.A., Bennett D.A. Statins, incident Alzheimer disease, change in cognitive function, and neuropathology. Neurology 2008, 70:1795-1802.
4. Atzmon G., Gabriely I., Griener W., Davidson D., Schechter C., Brazilai N. Plasma HDL levels highly correlate with cognitive function in exceptional longevity. J. Gerontol. Ser. A Biol. Sci. Med. Sci. 2002, 57A:M712-M715.
5. Bahia V.S., Kok F., Marie S.N., Shinjo S., Caramelli P., Nitrini R. Polymorphisms of APOE and LRP genes in Brazilian individuals with Alzheimer disease. Alzheimer's Dis. Assoc. Disord. 2008, 22:61-65.
6. Baldwin S., Farias S.T. Neuropsychological assessment in the diagnosis of Alzheimer's disease. Curr. Protocols Neurosci. 2009, 49:1031-1038.
7. Bales, K.R. Brain lipid metabolism, apolipoprotein E and the pathophysiology of Alzheimer's disease. Neuropharmacology, in press.
8. Banks W.A. Blood-brain barrier transport of cytokines: a mechanism for neuropathology. Curr. Pharm. Des. 2005, 11:973-984.
9. Baranowski M. Biological role of liver X receptors. J. Physiol. Pharmacol. 2008, 59(Suppl. 7):31-55.
10. Beach T.G. Physiologic origins of age-related β-amyloid deposition. Neurodegenerative Dis. 2008, 5:143-145.
11. Benarroch E.E. Brain cholesterol metabolism and neurologic disease. Neurology 2008, 71:1368-1373.
12. Bernick C., Katz R., Smith N.L., Rapp S., Bhadelia R., Carlson M., Kuller L.H. Statins and cognitive function in the elderly. Neurology 2005, 65:1388-1394.
13. Bertram L., Hsiao M., MCQueen M.B., Parkinson M., Mullin K., Blacker D., Tanzi R.E. The LDLR locus in Alzheimer's disease: a family-based study and meta-analysis of case-control data. Neurobiol. Aging 2007, 18:e18-e21.
14. Billings L.M., Green K.N., McGaugh J.L., LaFerla F.M. Learning decreases Aβ 56 and tau pathology and ameliorates behavioral decline in 3xTg-AD mice. J. Neurosci. 2007, 27:751-761.
15. Billings L.M., Oddo S., Green K.N., McGaugh J.L., LeFerla F.M. Intraneuronal Aβ causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron 2005, 45:675-688.
16. Bjorkhem I. Do oxysterols control cholesterol homeostasis?. J. Clin. Invest. 2002, 110:725-730.
17. Bjorkhem I. Are side-chain oxidized oxysterols regulators also in vivo?. J. Lipid Res. 2009, 50:S213-S218.
18. Bjorkhem I., Cedazo-Minguez A., Leoni V., Meaney S. Oxysterols and neurodegenerative disorders. Mol. Aspects Med. 2009, 30:171-179.
19. Bour A., Grootendorst J., Vogel E., Kelche C., Dodart J.-C., Bales K., Moreau P.H., Sullivan P.M., Mathis C. Middle-aged human apoE4 targeted-replacement mice show retention deficits on a wide range of spatial memory tasks. Behav. Brain Res. 2008, 193:174-182.
20. Brooks S.P., Pask T., Jones L., Dunnett S.B. Behavioural profiles of inbred mouse strains used as transgenic backgrounds. I: motor tests. Genes Brain Behav. 2004, 3:206-215.
21. Brouwers N., Sleegers K., Van Broeckhoven C. Molecular genetics of Alzheimer's disease: an update. Ann. Med. 2008, 18:1-22.
22. Burgess B.L., Parkinson P.F., Racke M.M., Hirsch-Reinshagen V., Fan J., Wong C., Stukas S., Theroux L., Chan J.Y., Donkin J., Wilkinson A., Balik D., Christie B., Poirier J., Lutjohann D., DeMattos R.B., Wellington C.L. ABCG1 influences the brain cholesterol biosynthetic pathway but does not affect amyloid precursor protein or apolipoprotein E metabolism in vivo. J. Lipid Res. 2008, 49:1254-1267.
23. Canevari L., Clark J.B. Alzheimer's disease and cholesterol: the fat connection. Neurochem. Res. 2007, 32:739-750.
24. Cao D., Fukuchi K., Wan H., Kim H., Li L. Lack of LDL receptor aggravates learning deficits and amyloid deposits in Alzheimer transgenic mice. Neurobiol. Aging 2006, 27:1632-1643.
25. Carlsson C.M., Gleason C.E., Hess T.M., Moreland K.A., Blazel H.M., Koscik R.L., Schreiber N.T.N., Johnson S.C., Atwood C.S., Puglielli L., Hermann B.P., McBride P.E., Stein J.H., Sager M.A., Asthana S. Effects of simvastatin on cerebrospinal fluid biomarkers and cognition in middle-aged adults at risk for Alzheimer's disease. J. Alzheimer's Dis. 2008, 13:187-192.
26. Carlsson C.M., Nondahl D.M., Klein B.E., McBride P.E., Sager M.A., Schubert C.R., Klein R., Cruickshanks K.J. increased atherogenic lipoproteins are associated with cognitive impairment: effects of statins and subclinical atherosclerosis. Alzheimer's Dis. Assoc. Disord. 2009, 23:11-17.
27. Chafekar S.M., Baas F., Scheper W. Oligomer-specific aβ toxicity in cell models is mediated by selective uptake. Biochim. Biophys. Acta 2008, 1782:523-531.
28. Chen J.C., Edwards C.L., Vidyarthi S., Pitchumoni S., Trabizi S., Barboriak D., Charles H.C., Doriaswamy P.M. Learning and recall in subjects at genetic risk for Alzheimer's disease. J. Neuropsych. Clin. Neurosci. 2002, 14:58-63.
29. Chen X., Gawryluk J.W., Wagener J.F., Ghribi O., Geiger J.D. Caffeine blocks disruption of the blood brain barrier in a rabbit model of Alzheimer's disease. J. Neuroinflamm. 2008, 5:1-14.
30. Crawley J.N. What's Wrong with my Mouse? Behavioral Phenotyping of Transgenic and Knockout Mice 2000, Wiley-Liss, New York.
31. Darwish D.S., Wang D., Konat G.W., Schreurs B.G. Dietary cholesterol impairs memory and memory increases brain cholesterol and sulfatide levels. Behav. Neurosci. 2010, 124:115-123.
32. de Frias C.M., Bunce D., Wahlin A., Adolfsson R., Sleegers K., Cruts M., Van Broeckhoven C., Nilsson L.-G. Cholesterol and triglycerides moderate the effect of apolipoprotein E on memory functioning in older adults. J. Gerentol. Psychol. Sci. 2007, 62B:P112-P118.
33. Deane R., Bell R.D., Sagare A., Zlokovic B.V. Clearance of amyloid-β across the blood-brain barrier: implications for therapies in Alzheimer's disease. CNS Neurol. Disord. Drug Targets 2009, 8:16-30.
34. Deary I.J., Whiteman M.C., Pattie A., Starr J.M., Hayward C., Wright A.F., Carothers A., Whalley L.J. Cognitive change and the APOE e{open}4 allele. Nature 2002, 418:932.
35. Despande A., Mina E., Glabe C., Busciglio J. Different conformations of amyloid β induce toxicity by distinct mechanisms in human cortical neurons. J. Neurosci. 2006, 26:6011-6018.
36. Deyo R.A., Straube K.T., Disterhoft J.F. Nimodipine facilitates associative learning in aging rabbits. Science 1989, 243:809-811.
37. Di Filippo M., Sarchielli P., Picconi B., Calabresi P. Neuroinflammation and synaptic plasticity: theoretical basis for a movel, immune-centred, therapeutic approach to neurological disorders. Trends Pharmacol. Sci. 2008, 29:402-412.
38. Dietschy J.M. Central nervous system: cholesterol turnover, brain development and neurodegeneration. Biol. Chem. 2009, 390:287-293.
39. Dietschy J.M., Turley S.D. Cholesterol metabolism in the brain. Curr. Opin. Lipidol. 2001, 12:105-112.
40. Dietschy J.M., Turley S.D. Cholesterol metabolism in the central nervous system during early development and in the mature animal. J. Lipid Res. 2004, 45:1375-1397.
41. Dik M.G., Jonker C., Comijs H.C., Bouter L.M., Twisk J.W.R., van Kamp G.J., Deeg D.J.H. Memory complaints and APOE-e{open}4 accelerate cognitive decline in cognitively normal elderly. Neurology 2001, 57:2217-2222.
42. Dineley K.T., Xia X., Bui D., Sweatt J.D., Zheng H. Accelerated plaque accumulation, associative learning deficits, and up-regulation of α7 nicotinic receptor protein in transgenic mice co-expressing mutant human preseniline 1 and amyloid precursor proteins. J. Biol. Chem. 2002, 277:22768-22780.
43. Dufour F., Liu Q.-Y., Gusev P., Alkon D.L., Atzori M. Cholesterol-enriched diet affects spatial learning and synaptic function in hippocampal synapses. Brain Res. 2006, 1103:88-98.
44. Eddins D., Klein R.C., Yakel J.L., Levin E.D. Hippocampal infusion of apolipoprotein E peptides induce long-lasting cognitive impairment. Brain Res. Bull. 2009, 79:111-115.
45. Elder G.A., Cho J.Y., English D.F., Franciosi S., Schmeidler J., Gama Sosa M.A., De Gasperi R., Fisher E.A., Mathews P.M., Haroutunian V., Buxbaum J.D. Elevated plasma cholesterol does not affect brain Aβ in mice lacking the low-density lipoprotein receptor. J. Neurochem. 2007, 102:1220-1231.
46. Elias P.K., Elias M.F., D'Agostino R.B., Sullivan L.M., Wolf P.A. Serum cholesterol and cognitive performance in the Framingham heart study. Psychosom. Med. 2005, 67:24-30.
47. Endo Y., Nishimura J.-I., Kimura F. Impairment of maze learning in rats following long-term glucocorticoid treatments. Neurosci. Lett. 1996, 203:199-202.
48. Esler W.P., Marshall J.R., Stimson E.R., Ghilardi J.R., Vinters H.V., Mantyh P.W., Maggio J.E. Apolipoprotein E affects amyloid formation but not amyloid growth in vitro: mechanistic implications for ApoE4 enhanced amyloid burden and risk for Alzheimer's disease. Amyloid: J. Protein Folding Disord. 2002, 9:1-12.
49. Evans M.A., Golomb B.A. Statin-associated adverse cognitive effects: survey results from 171 patients. Pharmacotherapy 2009, 29:800-811.
50. Evans R.M., Emsley C.L., Gao S., Sahota A., Hall K.S., Farlow M.R., Hendrie H. Serum cholesterol, APOE genotype, and the risk of Alzheimer's disease: a population-based study of African Americans. Neurology 2000, 54:240-242.
51. Fassbender K., Stroick M., Bertsch T., Ragaschke A., Kuehl S., Walter S., Walter J., Brechtel K., Muehlhauser F., von Bergmann K., Lutjohann D. Effects of statins on human cerebral cholesterol metabolism and secretion of Alzheimer amyloid peptide. Neurology 2002, 59:1257-1258.
52. Feldman H.H., Doody R.S., Kivipelto M., Sparks D.L., Waters D.D., Jones R.W., Schwam E., Schindler R., Hey-Hadavi J., DeMicco D.A., Breazna A. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology 2010, 74:956-964.
53. Fernandez del Pozo V., Alvarez Alvarez M., Fernandez Martinez M., Galados Alcelay L., Gomez Busto F., Pena J.A., Alfonso-Snachez M.A., Zarranz Imirizaldu J.J., de Pancordo M.M. Polymorphism in the cholesterol 24S-hydroxylase gene (CYP46A1) associated with the APOEpsilon3 allele increases the risk of Alzheimer's disease and of mild cognitive impairment progressing to Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 2006, 21:81-87.
54. Flory J.D., Manuck S.B., Ferrell R.E., Ryan C.M., Muldoon M.F. Memory performance and the apolipoprotein E polymorphism in a community sample of middle-aged adults. Am. J. Med. Genet. (Neuropsych. Genet.) 2000, 96:707-711.
55. Foster T.C. Biological markers of age-related memory deficits. Treatment of senescent physiology. CNS Drugs 2006, 20:153-166.
56. Frears E.R., Stephens D.J., Walters C.E., Davies H., Austen B.M. The role of cholesterol in the biosynthesis of β-amyloid. NeuroReport 1999, 10:1699-1705.
57. Fu B.Y., Ma S.L., Tang N.L., Tam C.W., Lui V.W., Chiu H.F., Lam L.C. Cholesterol 24-hydroxylase (CYP46A1) polymorphisms are associated with faster cognitive deterioration in Chinese older persons: a two-year follow up study. Int. J. Geriatr. Psychiatry 2009, 24:921-926.
58. Ghribi O., Golovko M.Y., Larsen B., Schrag M., Murphy E.J. Deposition of iron and β-amyloid plaques is associated with cortical cellular damage in rabbits fed with long-term cholesterol-enriched diets. J. Neurochem. 2006, 99:438-449.
59. Ghribi O., Larsen B., Schrag M., Herman M.M. High cholesterol content in neurons increases BACE, β-amyloid, and phosphorylated tau levels in rabbit hippocampus. Exp. Neurol. 2006, 200:460-467.
60. Goritz C., Mauch D.H., Pfrieger F.W. Multiple mechanisms mediate cholesterol-induced synaptogenesis in a CNS neuron. Mol. Cell. Neurosci. 2006, 29:190-201.
61. Gormezano I., Kehoe E.J., Marshall B.S. Twenty years of classical conditioning research with the rabbit. Progress in Psychobiology and Physiological Psychology 1983, 197-275. Academic Press, New York. J.M. Sprague (Ed.).
62. Gotto A.M., Farmer J.A. Pleiotropic effects of statins: do they matter?. Curr. Opin. Lipidol. 2001, 12:391-394.
63. Gouras G.K., Almeida C.G., Takahashi R.H. Intraneuronal Aβ accummulation and origin of plaques in Alzheimer's disease. Neurobiol. Aging 2005, 26:1235-1244.
64. Granholm A.-C., Bimonte-Nelson H.A., Moore A.B., Nelson M.E., Freeman L.R., Sambamurti K. Effects of a saturated fat and high cholesterol diet on memory and hippocampal morphology in middle-aged rats. J. Alzheimer's Dis. 2008, 14:133-145.
65. Grimm M.O.W., Grimm H.S., Hartmann T. Amyloid beta as a regulator of lipid homeostasis. Trends Mol. Med. 2007, 13:337-344.
66. Grootendorst J., Bours A., Vogel E., Kelche C., Sullivan P.M., Dodart J.-C., Bales K., Mathis C. Human apoE targeted replacement mouse lines: h-apoE4 and h-apoE3 mice differ on spatial memory performance and avoidance behavior. Behav. Brain Res. 2005, 159:1-14.
67. Haag M.D.H., Hofman A., Koudstaal P.J., Stricker B.H.C., Breteler M.M.B. Statins as associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam study. J. Neurol. Neurosurg. Psych. 2009, 80:13-17.
68. Haass C., Selkoe D.J. Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid β-peptide. Nat. Rev. Mol. Cell Biol. 2007, 8:101-112.
69. Hansson G.K., Robertson A.-K.L., Soderberg-Naucler C. Inflammation and atherosclerosis. Ann. Rev. Pathol. Mech. Dis. 2008, 1:297-329.
70. Harris-White M.E., Balverde Z., Lim G.P., Kim P., Miller S.A., Hammer H., Galasko D., Frautschy S.A. Role of LRP in TGFbeta2-mediated neuronal uptake of Abeta and effects on memory. J. Neurosci. Res. 2004, 77:217-228.
71. Hartman R.E., Wozniak D.F., Nardi A., Olney J.W., Sartorius L., Holtzman D.M. Behavioral phenotyping of GFAP-ApoE3 and -ApoE4 transgenic mice: ApoE4 mice show profound working memory impairments in the absence of Alzheimer's-like neuropathology. Exp. Neurol. 2001, 170:326-344.
72. Hartmann H., Eckert A., Muller W. Apolipoprotein E and cholesterol affect neuronal calcium signalling: the possible relationship to β-neurotoxicity. Biochem. Biophys. Res. Commun. 1994, 200:1185-1192.
73. Hartmann T. Cholesterol, Aβ and Alzheimer's disease. Trends Neurosci. 2001, 11:S45-S48.
74. Hartmann T. Role of amyloid precursor protein, amyloid-β and γ-secretase in cholesterol maintenance. Neurodegenerative Dis. 2006, 3:305-311.
75. Heverin M., Meaney S., Lutjohann D., Diczfalusy U., Wahren J., Bjorkhem I. Crossing the barrier: net flux of 27-hydroxycholesterol into the human brain. J. Lipid Res. 2005, 46:1047-1052.
76. Hirsch-Reinshagen V., Wellington C.L. Cholesterol metabolism, apolipoprotein E, adenosine triphosphate-binding cassette transporters, and Alzheimer's disease. Curr. Opin. Lipidol. 2007, 18:325-332.
77. Hoglund K., Thelen K.M., Syversen S., Sjogren M., von Bergmann K., Wallin A., Vanmechelen E., Vanderstichele H., Lutjohann D., Blennow K. The effect of simvastatin treatment on the amyloid precursor protein and brain cholesterol metabolism in patients with Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 2005, 19:256-265.
78. Hoshino T., Kamino K., Matsumoto M. Gene dose effect of the APOE-e{open}4 allele on plasma HDL cholesterol level in patients with Alzheimer's disease. Neurobiol. Aging 2002, 23:41-45.
79. Hoyer S., Riederer P. Alzheimer disease - no traget for statin treatment. A mini review. Neurochem. Res. 2007, 32:695-706.
80. Hudry E., Van Dam D., Kulik W., De Deyn P.P., Stet F.S., Ahouansou O., Benraiss A., Delacourte A., Bougneres P., Aubourg P., Cartier N. Adeno-associated virus gene therapy with cholesterol 24-hydroxylase reduces the amyloid pathology before or after onset of amyloid plaques in mouse models of Alzheimer's disease. Mol. Therapy 2009, 18:44-53.
81. Jacova C., Kertesz A., Blair M., Fisk J.D., Feldman H.H. Neuropsychological testing and assessment of dementia. Alzheimer's Dementia 2007, 3:299-317.
82. Jaeger L.B., Dohgu S., Hwang M.C., Farr S.A., Murphy M.P., Fleegal-Demotta M.A., Lynch J.L., Robinson S.M., Niehoff M.L., Johnson S.N., Kumar V.B., Banks W.A. Testing the neurovascular hypothesis of Alzheimer's disease: LRP-1 antisense reduces blood-brain barrier clearance, increases brain levels of amyloid-beta protein, and impairs cognition. J. Alzheimer's Dis. 2010, 17:553-570.
83. Jarvik G.P., Wijsman E.M., Kukull W.A., Schellenberg G.D., Yu C., Larson E.B. Interactions of apolipoprotein E genotype, total cholesterol level, age, and sex in prediction of Alzheimer's disease. Neurology 1995, 45:1092-1096.
84. Jasinska M., Owczarek J., Orszulak-Michalak D. Statins: a new insight into their mechanisms of action and consequent pleiotropic effects. Pharmacol. Rep. 2007, 59:483-499.
85. Jaya Prasanthi R.P., Schommer E., Thomasson S., Thompson A., Feist G., Ghribi O. Regulation of β-amyloid levels in the brain of cholesterol-fed rabbit, a model system for sporadic Alzheimer's disease. Mech. Ageing Dev. 2008, 29:649-655.
86. Jessup W., Kritharides L., Stocker R. Lipid peroxidation in atherogenesis: an overview. Biochem. Soc. Trans. 2004, 32:134-138.
87. Jiang Q., Lee C.Y.D., Mandrekar S., Wilkinson B., Cramer P., Zelcer N., Mann K., Lamb B., Wilson T.M., Collins J.L., Richardson J.C., Smith J.D., Comery T.A., Riddell D., Holtzman D.M., Tontonoz P., Landreth G.E. ApoE promotes the proteolytic degradation of Aβ. Neuron 2008, 58:681-693.
88. Jick H., Zornberg G.L., Jick S.S., Seshardi S., Drachman D.A. Statins and the risk of dementia. Lancet 2000, 356:1627-1631.
89. Joseph J., Shukitt-Hale B., Denisova N.A., Martin A., Perry G., Smith M.A. Copernicus revisited: amyloid beta in Alzheimer's disease. Neurobiol. Aging 2001, 22:131-146.
90. Juva K., Verkkoniemi A., Viramo P., Polvikoski T., Kainulainen K., Kontula K., Sulkava R. Apolipoprotein E, cognitive function, and dementia in a general population aged 85 years and over. Int. Psychogeriatr. 2000, 12:379-387.
91. Kainuma M., Fujimoto M., Sekiya N., Tsuneyama K., Cheng C., Takano Y., Tersawa K., Shimada Y. Cholesterol-fed rabbit as a unique model of nonalcoholic, nonobese, non-insulin-resistant fatty liver disease with characteristic fibrosis. J. Gastroenterol. 2006, 41:971-980.
92. Kane K.A., Robinson G.B. Effect of chronic nimodipine on spatial learning and on long-term potentiation. Behav. Brain Res. 1999, 98:95-101.
93. Kayed R., Head E., Thompson J.L., McIntire T.M., Milton S.C., Cotman C.W., Glabe C.G. Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis. Science 2003, 300:486-489.
94. Kessler A.R., Kessler B., Yehuda S. In vivo modulation of brain cholesterol level and learning performance by a novel plant lipid: indication of interactions between hippocampal-cortical cholesterol and learning. Life Sci. 1986, 38:1185-1192.
95. Kim J.-H., Basak J.M., Holtzman D.M. The role of apolipoprotein E in Alzheimer's disease. Neuron 2009, 63:287-303.
96. Kim K.W., Youn J.C., Jhoo J.H., Lee D.Y., Lee K.U., Lee J.H., Woo J.I. Apolipoprotein E e{open}4 Allele is not associated with the cognitive impairment in community-dwelling normal elderly individuals. Int. J. Geriatr. Psychiatry 2002, 17:635-640.
97. Kim W.S., Weickert C.S., Garner B. Role of ATP-binding cassette transporters in brain lipid transport and neurological disease. J. Neurochem. 2008, 104:1145-1166.
98. Kirsch C., Eckert G.P., Koudinov A.R., Muller W.E. Brain cholesterol, statins and Alzheimer's disease. Pharmacopsychiatry 2003, 36:S113-S119.
99. Kivipelto M., Helkala E.-L., Hanninen T., Laakso M.P., Hallikainen M., Alhainen K., Soininen H., Tuomilehto J., Nissinen A. Midlife vascular risk factors and late-life mild cognitive impairment: a population-based study. Neurology 2001, 56:1683-1689.
100. Koladiya R.U., Jaggi A.S., Singh N., Sharma B.K. Ameliorative role of atorvastatin and pitavastatin in L-methionine induced vascular dementia in rats. BMC Pharmacol. 2008, 9:8-14.
101. Kolsch H., Heun R., Kerksiek A., Bergmann K.V., Maier W., Lutjohann D. Altered levels of plasma 24S- and 27-hydroxycholesterol in demented patients. Neurosci. Lett. 2004, 368:303-308.
102. Kotti T.J., Ramirez D.M.O., Pfeiffer B.E., Huber K.M., Russell D.W. Brain cholesterol turnover required for geranylgeraniol production and learning in mice. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:3869-3874.
103. Koudinov A.R., Koudinova N.V. Essential role of cholesterol in synaptic plasticity and neuronal degeneration. FASEB J. 2001, 15:1858-1860.
104. Lacor P.N., Buniel M.C., Furlow P.W., Clemente A.S., Velasco P.T., Wood M., Viola K.L., Klein W.L. Aβ oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. J. Neurosci. 2007, 27:796-807.
105. LaFerla F.M., Green K.N., Oddo S. Intracellular amyloid-β in Alzheimer's disease. Nat. Rev. Neurosci. 2007, 8:499-509.
106. Ledesma M.D., Dotti C.G. Amyloid excess in Alzheimer's disease: what is cholesterol to be blamed for?. FEBS Lett. 2006, 580:5525-5532.
107. Lefterov, I., Fitz, N.F., Cronican, A., Lefterov, P., Staufenbiel, M., Koldamova, R., 2009. Memory deficits in APP23/Abca1+/- mice correlate with the level of Abeta oligomers. ASN Neuro 1.
108. Lesne S., Koh M.T., Kotilinek L., Kayed R., Glabe C.G., Yang A., Gallagher M., Ashe K.H. A specific amyloid-β protein assembly in the brain impairs memory. Nature 2006, 440:352-357.
109. Lesser G.T., Haroutunian V., Purohit D.P., Beeri M.S., Schmeidler J., Honkanen L., Neufeld R., Libow L. Serum lipid levels are related to Alzheimer's pathology in nursing home residents. Dement. Geriatr. Cogn. Disord. 2009, 27:42-49.
110. Li L., Cao D., Garber D.W., Kim H., Fukuchi K. Association of aortic atherosclerosis with cerebral β-amyloidosis and learning deficits in a mouse model of Alzheimer's disease. Am. J. Pathol. 2003, 163:2155-2164.
111. Li L., Cao D., Kim H., Lester R., Fukuchi K. Simvastatin enhances learning and memory independent of amyloid load in mice. Ann. Neurol. 2006, 60:729-739.
112. Liao J.K., Laufs U. Pleiotropic effects of statins. Annu. Rev. Pharmacol. Toxicol. 2005, 45:89-118.
113. Liu, F., Pardo, L.M., Schuur, M., Sanchez-Juan, P., Isaacs, A., Sleegers, K., de Koning, I., Zorkoltseva, I.V., Axenovich, T.I., Wittman, J.C.M., Janssens, A.C.J.W., van Sweiten, J.C., Aulchenko, Y.S., Oostra, B.A., Van Duijn, C.M., 2008. The apolipoprotein E gene and its age-specific effects on cognitive function. Neurobiol. Aging.
114. Liu Y., Peterson D.A., Schubert D. Amyloid β peptide alters intracellular vesicle trafficking and cholesterol homeostasis. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:13266-13271.
115. Lominska C., Levin J.A., Wang J., Sikes J., Kao C., Smith J.D. Apolipoprotein E deficiency effects on learning in mice are dependent upon the background strain. Behav. Brain Res. 2001, 120:23-34.
116. Lu D., Qu C., Goussev A., Jiang H., Lu C., Schallert T., Mahmood A., Chen J., Chopp M. Statins increase neurogenesis in the dentate gyrus, reduce delayed neuronal death in the hippocampal CA3 region, and improve spatial learning in rat after traumatic brain injury. J. Neurotrauma 2007, 24:1132-1146.
117. Lu J., Wu D.-M., Zheng Y.-L., Sun D.-X., Hu B., Shan Q., Zhang Z.-F., Fan S.-H. Trace amounts of copper exacerbate beta amyloid-induced neurotoxicity in the cholesterol-fed mice through TNF-mediated inflammatory pathway. Brain Behav. Immun. 2009, 23:193-203.
118. Lukiw W.J., Pappolla M., Pelaez R.P., Bazan N.G. Alzheimer's disease-a dysfunction in cholesterol and lipid metabolism. Cell. Mol. Neurobiol. 2005, 25:475-483.
119. Ma H., Lesne S., Kotilinek L., Steidl-Nicols J.V., Sherman M., Younkin L., Younkin S., Forster C., Sergeant N., Delacourte A., Vassar R., Citron M., Kofuji P., Boland L.M., Ashe K.H. Involvment of β-site APP cleaving emzyme 1 (BACE1) in amyloid precusor protein-mediated enhancement of memory and activity-dependent synaptic plasticity. Proc. Natl. Acad. Sci. 2007, 104:8167-8172.
120. Mahfouz M.M., Kummerow F.A. Cholesterol-rich diets have different effects on lipid peroxidation, cholesterol oxides, and antioxidant enzymes in rats and rabbits. J. Nutr. Biochem. 2000, 11:293-302.
121. Martins I.J., Berger T., Sharman M.J., Verdile G., Fuller S.J., Marins R.N. Cholesterol metabolism and transport in the pathogenesis of Alzheimer's disease. J. Neurochem. 2009, 111:1275-1308.
122. Masse I., Bordet R., Deplanque D., Al Khedr A., Richard F., Libersa C., Pasquier F. Lipid lowering agents are associated with a slower cognitive decline in Alzheimer's disease. J. Neurol. Neurosurg. Psych. 2005, 76:1624-1629.
123. Mayeux R., Small S.A., Tang M.-X., Tycko B., Stern Y. Memory performance in healthy elderly without Alzheimer's disease: effects of time and apolipoprotein-E. Neurobiol. Aging 2001, 22:683-689.
124. McDowell I., Kristjansson E. Mental status testing. Measuring Health: A Guide to Rating Scales and Questionnaires 1996, 287-334. Oxford University Press, New York. I. McDowell, C. Newell (Eds.).
125. McLaurin J., Darabie A.A., Morrison M.R. Cholesterol, a modulator of membrane-associated aβ-fibrillogenesis. Pharmacopsychiatry 2003, 36:S130-S135.
126. Micale V., Scapagnini G., Colombrita C., Mazzola C., Alkon D.L., Drago F. Behavioral effects of dietary cholesterol in rats tested in experimental models of mild stress and cognition tasks. Eur. Neuropsychopharmacol. 2008, 18:462-471.
127. Mielke M.M., Zandi P.P., Sjogren M., Gustafson D., Ostling S., Steen B., Skoog I. High total cholesterol levels in late life associated with a reduced risk of dementia. Neurology 2005, 64:1689-1695.
128. Miller S., Wehner J.M. Cholesterol treatment facilitates spatial learning performance in DBA/2Ibg mice. Pharmacol. Biochem. Behav. 1994, 49:257-261.
129. Morgan D. Learning and memory deficits in APP transgenic mouse models of amyloid deposition. Neurochem. Res. 2003, 28:1029-1034.
130. Morris R. Developments of a water-maze procedure for studying spatial learning in the rat. J. Neurosci. Methods 1984, 11:47-60.
131. Mulder M., Jansen P.J., Janssen B.J., van de Berg W.D., van der Boom H., Havekes L.M., de Kloet R.E., Ramaekers F.C., Blokland A. Low-density lipoprotein receptor-knockout mice display impaired spatial memory associated with a decreased synaptic density in the hippocampus. Neurobiol. Dis. 2004, 16:212-219.
132. Muldoon M.F., Barger S.D., Ryan C.M., Flory J.D., Lehoczky J.P., Matthews K.A., Manuck S.B. Effects of lovastatin on cognitive function and psychological well-being. Am. J. Med. 2000, 108:538-547.
133. Muldoon M.F., Ryan C.M., Matthews K.A., Manuck S.B. Serum cholesterol and intellectual performance. Psychosom. Med. 1997, 59:382-387.
134. Näslund J., Haroutunian V., Mohs R., Davis K.L., Davies P., Greengard P., Buxbaum J.D. Correlation between elevated levels of amyloid β-peptide in the brain and cognitive decline. JAMA 2000, 283:1571-1577.
135. Nayler W.G. Review of preclinical data of calcium channel blockers and atherosclerosis. J. Cardiovasc. Pharmacol. 1999, 33. S7-S-11.
136. Notkola I.-L., Sulkava R., Pekkanen J., Erkinjunti T., Ehnholm C., Kivinen P., Tuomilehto J., Nissinen A. Serum total cholesterol, apolipoprotein Ee{open}4 allele, and Alzheimer's disease. Neuroepidemiology 1998, 17:14-20.
137. O'Brien W.T., Xu G., Batta A., Tint G.S., Salen G., Dyer C.A., Kendler A., Servatius R.J. Developmental sensitivity of associative learning to cholesterol synthesis inhibitors. Behav. Brain Res. 2002, 129:141-152.
138. Obrenovich M.E., Joseph J.A., Atwood C.S., Perry G., Smith M.A. Amyloid-β: a (life) preserver for the brain. Neurobiol. Aging 2002, 23:1097-1099.
139. Panza F., D'Introno A., Colacicco A.M., Capurso C., Pichichero G., Capurso S.A., Capurso A., Solfrizzi V. Lipid metabolism in cognitive decline and dementia. Brain Res. Rev. 2006, 51:275-292.
140. Papassotiropoulos A., Lutjohann D., Bagli M., Locatelli S., Jessen F., Buschfort R., Ptok U., Bjorkhem I., von Bergmann K., Heun R. 24S-hydroxycholesterol in cerebrospinal fluid is elevated in early stages of dementia. J. Psychiatr. Res. 2002, 36:27-32.
141. Papassotiropoulos A., Wollmer M.A., Tsolaki M., Brunner F., Molyva D., Lutjohann D., Nitsch R., Hock C. A cluster of cholesterol-related genes confers susceptibility for Alzheimer's disease. J. Clin. Psychiatry 2005, 66:940-947.
142. Parale G.P., Baheti N.N., Kulkarni P.M., Panchal N.V. Effects of atorvastatin on higher functions. Eur. J. Clin. Pharmacol. 2006, 62:259-265.
143. Parkinson, P.F., Kannangara, T.S., Eadie, B.D., Burgess, B.L., Wellington, C.L., Christie, B.R., 2009. Cognition, learning behaviour and hippocampal synaptic plasticity are not disrupted in mice over-expressing the cholesterol transporter ABCG1. Lipids in Health and Disease 8.
144. Pavlov I.P. Conditioned Reflexes: An Investigation of the Physiological Activity of the Cerebral Cortex (G.V. Anrep, Trans.) 1927, Oxford University Press, London.
145. Pearson H.A., Peers C. Physiological roles for amyloid β peptides. J. Physiol. (Lond.) 2006, 575:5-10.
146. Perry L.A., Stigger C.B., Ainsworth B.E., Zhang J. No association between cognitive acheivements, academic performance and serum cholesterol concentrations among school-aged children. Nutr. Neurosci. 2009, 12:160-166.
147. Pfrieger F.W. Outsourcing in the brain: do neurons depend on cholesterol delivery by astrocytes?. BioEssays 2002, 25:72-78.
148. Pickering M., O'Connor J.J. Pro-inflammatory cytokines and their effects in the dentate gyrus. Prog. Brain Res. 2007, 163:339-354.
149. Poirier J. Apolipoprotein E, cholesterol transport and synthesis in sporadic Alzheimer's disease. Neurobiol. Aging 2005, 26:355-361.
150. Qiu S., Korwek K.M., Weeber E.J. A fresh look at an ancient family: emerging roles for low density lipoprotein receptors in synaptic plasticity and memory formation. Neurobiol. Learn. Mem. 2006, 85:16-29.
151. 2+ channel blocker amlodipine facilitates learning and memory in mice. Eur. J. Pharmacol. 2000, 399:57-63.
152. Quartermain D., deSoria V.G., Kwan A. Calcium channel antagonists enhance retention of passive avoidance and maze learning in mice. Neurobiol. Learn. Mem. 2001, 75:77-90.
153. Rader D.J., Daugherty A. Translating molecular discoveries into new therapies for atherosclerosis. Nature 2008, 451:904-913.
154. Raffai R.L., Weisgraber K.H. Cholesterol: from heart attacks to Alzheimer's disease. J. Lipid Res. 2003, 44:1423-1430.
155. Rafnsson S.B., Deary I.J., Fowkes F.G. Peripheral arterial disease and cognitive function. Vasc. Med. 2009, 14:51-61.
156. Reid P.C., Urano Y., Kodama T., Hamakubo T. Alzheimer's disease: cholesterol, membrane rafts, isoprenoids and statins. J. Cell. Mol. Med. 2007, 11:383-392.
157. Reitan R.M., Shipley R.E. The relationship of serum cholesterol changes to psychological abilities. J. Gerontol. 1963, 18:350-357.
158. Reynolds C.A., Hong M.-G., Eriksson U.K., Blennow K., Bennet A.M., Johansson B., Malmburg B., Berg S., Wiklund F., Gatz M., Pedersen N.L., Prince J.A. A survey of ABCA1 sequence variation confirms association with dementia. Hum. Mutat. 2009, 30:1-7.
159. Reynolds C.A., Prince J.A., Feuk L., Brookes A.J., Gatz M., Pedersen N.L. Longitudinal memory performance during normal aging: twin association models of APOE and other Alzheimer candidate genes. Behav. Genet. 2006, 36:185-194.
160. Riddell D.R., Zhou H., Comery T.A., Kouranova E., Lo C.F., Warwick H.K., Ring R.H., Kirksey Y., Aschmies S., Xu J., Kubek K., Hirst W.D., Gonzales C., Chen Y., Murphy E., Leonard S., Vasylyev D., Oganesian A., Martone R.L., Pangalos M.N., Reinhart P.H., Jacobsen J.S. The LXR agonist TO901317 selectively lowers hippocampal Aβ42 and improves memory in the Tg2576 mouse model of Alzheimer's disease. Mol. Cell. Neurosci. 2007, 34:621-628.
161. Robakis N.K. Are Aβ and Its derivatives causative agents or innocent bystanders in AD?. Neurodegenerative Dis. 2010, 7:32-37.
162. Robinson S.R., Bishop G.M. Aβ as a bioflocculant: implications for the amyloid hypothesis of Alzheimer's disease. Neurobiol. Aging 2002, 23:1051-1072.
163. Rodriguez E., Mateo I., Llorca J., Sanchez-Quintana C., Infante J., Berciano J., Combarros O. No association between low density lipoprotein receptor genetic variants and Alzheimer's disease risk. Am. J. Med. Genet. (Neuropsych. Genet.) 2006, 141B:541-543.
164. Roher A.E., Kuo Y.-M., Kokjohn K.M., Emmerling M.R., Gracon S. Amyloid and lipids in the pathology of Alzheimer disease. Amyloid: J. Protein
165. Romero J.R., Beiser A., Seshardi S., Benjamin J., Polak J.F., Vasan R.S., Au R., DeCarli C., Wolf P.A. Carotid artery atherosclerosis. MRI indices of brain ischemia, aging, and cognitive impairment: the Framingham study. Stroke 2009, 40:1590-1596.
166. Ronald J.A., Chen Y., Bernas L., Kizler H.H., Rogers K.A., Hegele R.A., Rutt B.K. Clinical field-strength MRI of amyloid plaques induced by low-level cholesterol feeding in rabbits. Brain 2009, 132:1346-1354.
167. Russell D.W., Halford R.W., Ramirez D.M.O., Shah R., Kotti T. Cholesterol 24-hydroxylase: an enzyme of cholesterol turnover in the brain. Annu. Rev. Biochem. 2009, 78:1017-1040.
168. Sagare A., Deane R., Bell R.D., Johnson B., Hamm K., Pendu R., Marky A., Lenting P.J., Wu Z., Zarcone T., Goate A., Mayo K., Perlmutter D., Coma M., Zhong Z., Zlokovic B.V. Clearance of amyloid-β by circulating lipoprotein receptors. Nat. Med. 2007, 13:1029-1031.
169. Salo A., Ylikoski R., Verkkoniemi A., Polvikoski T., Juva K., Rastas S., Kontula K., Kainulainen K., Niinisto L., Notkola I.-L., Sulkava R. Does apolipoprotein E influence learning and memory in the nondemented oldest old?. Int. Psychogeriatr. 2002, 13:451-459.
170. Savory J., Ghribi O., Herman M.M. Is amyloid β-peptide neurotoxic or neuroprotective and what is its role in the binding of metal ions?. Neurobiol. Aging 2002, 23:1089-1092.
171. Schachter M. Calcium antagonists and atherosclerosis. Int. J. Cardiol. 1997, 62:S9-S15.
172. Schafers M., Sorkin L. Effects of cytokines on neuronal excitability. Neurosci. Lett. 2008, 437:188-193.
173. Schmajuk N.A., Christiansen B.A. Eyeblink conditioning in rats. Physiol. Behav. 1990, 48:755-758.
174. Schreurs B.G., Smith-Bell C.A., Darwish D.S., Stankovic G., Sparks D.L. Classical conditioning of the rabbit's nictitating membrane response is a function of the duration of dietary cholesterol. Nutr. Neurosci. 2007, 10:159-168.
175. Schreurs B.G., Smith-Bell C.A., Darwish D.S., Stankovic G., Sparks D.L. High dietary cholesterol facilitates classical conditioning of the rabbit's nictitating membrane response. Nutr. Neurosci. 2007, 10:31-43.
176. Schreurs B.G., Smith-Bell C.A., Darwish D.S., Wang D., Burhans L., Gonzales-Joekes J., Deci S., Stankovic G., Sparks D.L. Cholesterol enhances classical conditioning of the rabbit heart rate response. Behav. Brain Res. 2007, 181:52-63.
177. Schreurs B.G., Smith-Bell C.A., Lochhead J., Sparks D.L. Cholesterol modifies classical conditioning of the rabbit (Oryctolagus cuniculus) nictitating membrane response. Behav. Neurosci. 2003, 117:1220-1232.
178. Servatius R.J., Beck K.D. Facilitated acquisition of the classically conditioned eyeblink response in male rats after systemic IL-1β. Integr. Physiol. Behav. Sci. 2003, 38:169-178.
179. Shankar G.M., Bloodgood B.L., Townsend M., Walsh D.M., Selkoe D.J., Sabatini B.L. Natural oligomers of the Alzheimer amyloid-β protein induce reversible synapse loss by modulating an NMDA-type glutamate receptor-dependent signaling pathway. J. Neurosci. 2007, 27:2866-2875.
180. Shankar G.M., Li S., Mehta T.H., Garcia-Munoz A., Shepardson N.E., Smith I., Brett F.M., Farrell M.A., Rowan M.J., Lemere C.A., Regan C.M., Walsh D.M., Sabatini B.L., Selkoe D.J. Amyloid-β protein dimers isolated directly from Alzheimer's brains impairs synaptic plasticity and memory. Nat. Med. 2008, 14:837-842.
181. Sharma S., Prasanthi J., Schommer E., Feist G., Ghribi O. Hypercholesterolemia-induced Aβ accumulation in rabbit brain is associated with alteration in IGF-1 signaling. Neurobiol. Dis. 2008, 32:426-432.
182. Simons M., Keller P., Dichgans J., Schulz J.B. Cholesterol and Alzheimer's disease: Is there a link?. Neurology 2001, 57:1089-1093.
183. Singh-Manoux A., Gimeno D., Kivimaki M., Brunner E., Marmot M.G. Low HDL cholesterol is a risk factor for deficit and decline in memory in midlife: the Whitehall II study. Arteriosclerosis, Thrombosis Vasc. Biol. 2008, 28:1556-1562.
184. Sjogren M., Mielke M., Gustafson D., Zandi P., Skoog I. Cholesterol and Alzheimer's disease-Is there a relation?. Mech. Ageing Dev. 2006, 127:138-147.
185. Skelton R.W. Bilateral cerebellar lesions disrupt conditioned eyelid responses in unrestrained rats. Behav. Neurosci. 1988, 102:586-590.
186. Small B.J., Graves A.B., McEvoy C.L., Crawford F.C., Mullan M., Mortimer J.A. Is ApoE-e{open}4 a risk factor for cognitive impairment in normal aging?. Neurology 2000, 54:2082-2088.
187. Solomon A., Kareholt I., Ngandu T., Winblad B., Nissinen A., Tuomilehto J., Soininen H., Kivipelto M. Serum cholesterol changes after midlife and late-life cognition. Neurology 2007, 68:751-756.
188. Solomon A., Kareholt I., Ngandu T., Wolozin B., MacDonald S.W.S., Winblad B., Nissinen A., Tuomilehto J., Soininen H., Kivipelto M. Serum cholesterol, statins and cognition in non-demented elderly. Neurobiol. Aging 2009, 30:1006-1009.
189. Solomon A., Kivipelto M. Cholesterol-modifying strategies for Alzheimer's disease. Expert Rev. Neurotherap. 2009, 9:695-709.
190. Solomon A., Kivipelto M., Wolozin B., Zhou J., Whitmer R.A. Midlife serum cholesterol and increased risk of Alzheimer's and vascular dementia three decades later. Dement. Geriatr. Cogn. Disord. 2009, 28:75-80.
191. Sparks D.L. Coronary artery disease, hypertension, ApoE and cholesterol: a link to Alzheimer's disease. Ann. N. Y. Acad. Sci. 1997, 826:128-146.
192. Sparks D.L. Cholesterol, copper, and accumulation of thioflavine s-reactive Alzheimer's-like amyloid β in rabbit brain. J. Mol. Neurosci. 2004, 24:97-104.
193. Sparks D.L. Cholesterol metabolism and brain amyloidosis: evidence for a role of copper in the clearance of Aβ through the liver. Curr. Alzheimer Res. 2007, 4:165-169.
194. Sparks D.L., Connor D.J., Browne P.J., Lopez J.E., Sabbagh M.N. HMG-CoA reductase inhibitors (statins) in the treatment of Alzheimer's disease and why it would be ill-advised to use one that crosses the blood-brain barrier. J. Nutr. Health Aging 2002, 6:324-331.
195. Sparks D.L., Connor D.J., Sabbagh M.N., Petersen R.B., Lopez J., Browne P. Circulating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer's disease: results of the Alzheimer's Disease Cholesterol-Lowering Treatment (ADCLT) trial. Acta Neurol. Scand. 2006, 114:s3-s7.
196. Sparks D.L., Kryscio R.J., Sabbagh M.N., Connor D.J., Sparks L.M., Liebsack C. Reduced risk of incident AD with elective statin use in a clinical trial cohort. Curr. Alzheimer Res. 2008, 5:416-421.
197. Sparks D.L., Kuo Y.-M., Roher A.E., Martin T.A., Lukas R.J. Alterations of Alzheimer's disease in the cholesterol-fed rabbit, including vascular inflammation. Preliminary observations. Ann. N. Y. Acad. Sci. 2000, 903:335-344.
198. Sparks D.L., Lochhead J., Horstman D., Wagoner T., Martin T. Water quality has a pronounced effect on cholesterol-induced accumulation of Alzheimer amyloid (aβ) in rabbit brain. J. Alzheimer's Dis. 2002, 4:523-529.
199. Sparks D.L., Martin T., Stankovic G., Waggoner T., Van Adel R. Influence of water quality on cholesterol induced systemic pathology. J. Nutr. Health Aging 2007, 11:189-193.
200. Sparks D.L., Scheff S.W., Hunsaker J.C., Liu H., Landers T., Gross D.R. Induction of Alzheimer-like β-amyloid immunoreactivity in the brains of rabbits with dietary cholesterol. Exp. Neurol. 1994, 126:88-94.
201. Sparks D.L., Schreurs B.G. Trace amounts of copper in water induce β-amyloid plaques and learning deficits in a rabbit model of Alzheimer's disease. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:11065-11069.
202. Stewart R., Russ C., Richards M., Brayne C., Lovestone S., Mann A. Apolipoprotein E genotype, vascular risk and early cognitive impairment in an African Caribbean population. Dement. Geriatr. Cogn. Disord. 2001, 12:251-256.
203. Teunissen C.E., de Vente J., von Bergmann K., Bosma H., Van Boxtel M.P.J., De Bruijn C., Jolles J., Steinbusch H.W.M., Lutjohann D. Serum cholesterol, precursors and metabolites and cognitive performance in an aging population. Neurobiol. Aging 2003, 24:147-155.
204. Thelen K.M., Laaksonen R., Paiva H., Lehtimaki T., Lutjohann D. High-dose statin treatment does not alter plasma marker for brain cholesterol metabolism in patients with moderately elevated plasma cholesterol levels. J. Clin. Pharmacol. 2006, 46:812-816.
205. Thirumangalakudi L., Prakasam A., Zhang R., Bimonte-Nelson H.A., Sambamurti K., Kindy M.S., Bhat N.R. High cholesterol-induced neuroinflammation and amyloid precursor protein processing correlate with the loss of working memory in mice. J. Neurochem. 2008, 106:475-485.
206. Upchurch M., Wehner J.M. DBA/2Ibg mice are incapable of cholinergically-based learning in the Morris water maze. Pharmacol. Biochem. Behav. 1988, 29:325-329.
207. van den Kommer T.N., Dik M.G., Comijs H.C., Fassbender K., Lutjohann D., Jonker C. Total cholesterol and oxysterols: early markers for cognitive decline in elderly?. Neurobiol. Aging 2009, 30:534-545.
208. van der Staay F.J., Steckler T. Behavioral phenotyping of mouse mutants. Behav. Brain Res. 2001, 125:3-12.
209. van Exel E., de Craen A.J.M., Gussekloo J., Houx P., Bootsma-van der Weil A., Macfarlane P.W., Blauw G.J., Westendorp R.G.J. Association between high-density lipoprotein and cognitive impairment in the oldest old. Ann. Neurol. 2002, 51:716-721.
210. Vanmierlo, T., Rutten, K., Dederen, J., Bloks, V.W., van Vark-van der Zee, L.C., Kuipers, F., Kiliaan, A., Blokland, A., Sijbrands, E.J.G., Steinbusch, H., Prickaerts, J., Lutjohann, D., Mulder, M. Liver X receptor activation restores memory in aged AD mice without reducing amyloid. Neurobiol. Aging, in press.
211. Veinbergs I., Everson A., Sagara Y., Masliah E. Neurotoxic effects of apolipoprotein E4 are mediated via dysregulation of calcium homeostasis. J. Neurosci. Res. 2002, 67:379-387.
212. Veinbergs I., Mallory M., Sagara Y., Masliah E. Vitamin E supplementation prevents spatial learning deficits and dendritic alterations in aged apolipoprotein E-deficient mice. Eur. J. Neurosci. 2000, 12:4541-4546.
213. Viviani B., Gardoni F., Marinovich M. Cytokines and neuronal ion channels in health and disease. Int. Rev. Neurobiol. 2007, 82:247-263.
214. Voikar V., Rauvala H., Ikonen E. Cognitive deficit and development of motor impairment in a mouse model of Niemann-Pick type C disease. Behav. Brain Res. 2002, 132:1-10.
215. Wahrle S., Das P., Nyborg A.C., McLendon C., Shoji M., Kawarabayashi T., Younkin L.H., Younkin S.G., Golde T.E. Cholesterol-dependent γ-secretase activity in buoyant cholesterol-rich membrane microdomains. Neurobiol. Dis. 2002, 9:11-23.
216. Walsh D.M., Selkoe D.J. Aβ oligomers-a decade of discovery. J. Neurochem. 2007, 101:1172-1184.
217. Wegiel J., Kuchna I., Nowicki K., Frackowiak J., Mazur-Kolecka B., Imaki H., Wegiel J., Mehta P.D., Silverman W.P., Reisberg B., deLeon M., Wisniewski T., Pirttilla T., Frey H., Lehtimaki T., Kivimaki T., Visser F.E., Kamphorst W., Potempska A., Bolton D., Currie J.R., Miller D.L. Intraneuronal Aβ immunoreactivity is not a predictor of brain amyloidosis-β or neurofibrillary degeneration. Acta Neuropathol. (Berl.) 2007, 113:389-402.
218. West R., Beeri M.S., Schmeidler J., Hannigan C.M., Angelo G., Grossman H.T., Rosendorff C., Silverman J.M. Better memory functioning associated with higher total and low-density lipoprotein cholesterol levels in very elderly subjects without the apolipoprotein e4 allele. Am. J. Geriatr. Psychiatry 2008, 16:781-785.
219. Whitmer R.A., Sidney S., Selby J., Johnston S.C., Yaffe K. Midlife cardiovascular risk factors and risk of dementia in late life. Neurology 2005, 64:277-281.
220. Wild K., Howieson D., Webbe F., Seeyle A., Kaye J. Status of computerized cognitive testing in aging: a systematic review. Alzheimer's Dement. 2008, 4:428-437.
221. Wilson R.S., Schnieder J.A., Barnes L.L., Beckett L.A., Aggarwal N.T., Cochran E.J., Berry-Kravis E., Bach J., Fox J.H., Evans D.A., Bennett D.A. The apolipoprotein E e{open}4 allele and decline in different cognitive systems during a 6-year period. Arch. Neurol. 2002, 59:1154-1160.
222. Wollmer M.A., Sleegers K., Ingelsson M., Zekanowski C., Brouwers N., Maruszak A., Brunner F., Huynh K.D., Kilander L., Brudin R.M., Hedlund M., Giedraitis V., Glaser A., Engelsborghs S., De Deyn P.P., Kapaki E., Tsolaki M., Daniilidou M., Molyva D., Paraskevas G.P., Thal D.R., Barcikowska M., Kuznicki J., Lannfelt L., Van Broeckhoven C., Nitsch R.M., Hock C., Papassotiropoulos A. Association study of cholesterol-related genes in Alzheimer's disease. Neurogenetics 2007, 8:179-188.
223. Wolozin B., Kellman W., Celesia G.C., Siegel G. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch. Neurol. 2000, 57:1439-1443.
224. Wood W.G., Igbavboa U., Eckert G.P., Muller W.E. Cholesterol-a Janus-faced molecule in the central nervous system. Handbook of Neurochemistry and Molecular Neurobiology: Neural Membrane and Transport 2007, 152-171. Springer, New York. N.E.A. Reith (Ed.).
225. Woodruff-Pak D.S., Agelan A., Del Valle L. A rabbit model of Alzheimer's disease: valid at neuropathological, cognitive, and therapeutic levels. J. Alzheimer's Dis. 2007, 11:371-383.
226. Woodruff-Pak D.S., Chi J., Li Y.-T., Pak M.H., Fanelli R.J. Nimodipine ameliorates impaired eyeblink classical conditioning in order rabbits in the long-delay paradigm. Neurobiol. Aging 1997, 18:641-649.
227. Wu C.-W., Liao P.-C., Lin C., Kuo C.-J., Chen S.-T., Cehn H.-I., Kuo Y.-M. Brain region-dependent increases in β-amyloid and apolipoprotein E levels in hypercholesterolemic rabbits. J. Neural. Transm. 2003, 110:641-649.
228. Xu G., Servatius R.J., Shefer S., Tint G.S., O'Brien W.T., Batta A.K., Salen G. Relationship between abnormal cholesterol synthesis and retarded learning in rats. Metabolism 1998, 47:878-882.
229. Xue Q.-S., Sparks D.L., Streit W.J. Microglial activation in the hippocampus of hypercholesterolemic rabbits occurs independent of increased amyloid production. J. Neuroinflamm. 2007, 4:20-30.
230. Yaffe K., Barret-Connor E., Lin F., Grady D. Serum lipoprotein levels, statin use, and cognitive function in older women. Arch. Neurol. 2002, 59:378-384.
231. Yanagisawa K. Cholesterol and pathological processes in Alzheimer's disease. J. Neurosci. Res. 2002, 70:361-366.
232. Yao Z.-X., Papadopoulos V. Function of β-amyloid in cholesterol transport: a lead to neurotoxicity. FASEB J. 2002, 16:1677-1679.
233. Yehuda S., Carasso R.L. Modulation of learning, pain thresholds, and thermoregulation in the rat by preparations of free purified α-linolenic and linoleic acids: determination of the optimal ω3-to-ω6 ratio. Proc. Natl. Acad. Sci. U.S.A. 1993, 90:10345-10349.
234. Yehuda S., Rabinovitz S., Motofsky D.I. Modulation of learning and neuronal membrane composition in the rat by essential fatty acid preparation: time-course analysis. Neurochem. Res. 1998, 23:627-634.
235. Zandi P.P., Sparks D.L., Khachaturian A.S., Tschanz J.T., Norton M., Steinberg M., Wesl-Bohmer K.A., Breitner J.C.S. Do statins reduce risk of incident dementia and Alzheimer's disease?. Arch. Gen. Psychiatry 2005, 62:217-224. Cache County Investigators.
236. Zatta P., Zambenedetti P., Stella M.P., Licastro F. Astrocytosis, microgliosis, metallothionein-I-II and amyloid expression in high cholesterol-fed rabbits. J. Alzheimer's Dis. 2002, 4:1-9.
237. Zerbinatti C.V., Wozniak D.F., Cirrito J., Cam J.A., Osaka H., Bales K.R., Zhuo M., Paul S.M., Holtzman D.M., Bu G. Increased soluble amyloid-β peptide and memory deficits in amyloid model mice overexpressing the low-density lipoprotein receptor-related protein. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:1075-1080.
238. Zhao S., Liao W., Xu N., Xu H., Yu C., Liu X., Li C. Polar metabolite of cholesterol induces rat cognitive dysfunctions. Neuroscience 2009, 164:398-403.
239. Zhou Y.-T., Zhang Z.-X., Chan P., He X.-M., Tang M.-N., Wu C.-B., Hong Z. Genetic association between low-density lipoprotein receptor-related protein gene polymorphisms and Alzheimer's disease in Chinese Han population. Neurosci. Lett. 2008, 444:109-111.
240. Zou F., Gopalraj R.K., Lok J., Zhu H., Ling I.F., Simpson J.F., Tucker H.M., Kelly J.F., Younkin S.G., Dickson D.W., Petersen R.C., Graff-Radford N.R., Bennet D.A., Crook J.E., Younkin S.G., Estus S. Sex-dependent association of a common low-density lipoprotein receptor polymorphism with RNA splicing efficiency in the brain and Alzheimer's disease. Hum. Mol. Genet. 2008, 17:929-935.